Key result
SGLT2i use linked to ~16% lower stroke risk vs other antidiabetics in T2D.
Why the study?
Use of SGLT2 inhibitors in adults with type 2 diabetes has recently been associated with decreased stroke risk, prompting investigation into their impact on stroke and TIA.
Does SGLT2i reduce the incidence of stroke and TIA in adults with Type 2 diabetes?
Cohort
Does SGLT2i reduce the incidence of stroke and TIA in adults with Type 2 diabetes?
Odds Ratio: 0.84 (95% CI 0.79–0.91)
p-value: p=<0.001
In adults with type 2 diabetes, SGLT2 inhibitors are associated with a lower incidence of stroke and TIA compared to other antidiabetic medications.
SGLT2 inhibitor use was associated with lower stroke incidence in T2D; hypothesis-generating and should not yet change practice.
Aims Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in adults with Type 2 diabetes (AwT2D) has recently been associated with decreased stroke risk. In this study, we investigate the impact of SGLT2i on stroke. Materials and Methods We conducted a cohort study using an electronic health record (EHR) representing 66 million patients to examine whether AwT2D have a lower incidence of stroke and/or transient ischemic attack (TIA) if treated with SGLT2i. All analyses were completed utilizing high‐dimensional propensity score matching to control for confounders. Results AwT2D treated with SGLT2i compared to other antidiabetic medications, assessed after 1 year, starting 2 weeks after the date of prescription of SGLT2i or other antidiabetic drug, had a significantly lower incidence of any stroke (Odds Ratio (OR): 0.84 with 95% Confidence Interval (CI) 0.79–0.91, p < 0.001), hemorrhagic stroke (OR: 0.72 with 95% CI 0.59–0.88, p < 0.001), ischemic stroke (OR: 0.86 with 95% CI 0.77–0.95, p = 0.005), and TIA (OR: 0.87 with 95% CI 0.80–0.95, p = 0.003). Conclusion Among AwT2D, those treated with SGLT2i had lower incidence of stroke and TIA compared with adults treated with other antidiabetic medications.
No takes yet. Share an insight, caveat, or question.
Ayers et al. (2026) conducted a cohort in Type 2 diabetes. SGLT2 inhibitors vs. Other antidiabetic medications was evaluated on Any stroke (OR 0.84, 95% CI 0.79-0.91, p=<0.001). SGLT2 inhibitors were associated with a lower incidence of any stroke compared to other antidiabetic medications in adults with Type 2 diabetes (OR 0.84; 95% CI 0.79-0.91; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: